Texas Elmiron Pigmentary Maculopathy injury lawyer
At F1000Prime, we continue to track the intersection of pharmaceutical safety and patient advocacy. The Elmiron (pentosan polysulfate sodium) pigmentary maculopathy crisis remains a defining example of delayed drug-injury recognition. For Texas patients and their families, understanding the legal and medical landscape in 2026 is critical. We’ve compiled the latest data on litigation trends, diagnostic protocols, and the evolving role of injury lawyers in holding manufacturers accountable.
How the Texas Elmiron MDL Changed Retinal Injury Litigation
The multidistrict litigation (MDL) for Elmiron cases, consolidated in the District of New Jersey, has directly impacted Texas plaintiffs. As of early 2026, over 1,200 cases remain active, with a significant portion originating from Texas plaintiffs who used Elmiron for interstitial cystitis (IC) for five years or longer. The MDL’s bellwether trials—expected to begin in late 2026—will test key arguments about whether Janssen Pharmaceuticals adequately warned of the dose-dependent risk of pigmentary maculopathy.
Texas injury lawyers now routinely recommend baseline retinal exams for any IC patient who took Elmiron before 2020, when the FDA finally updated the drug’s label. A 2025 study in Retina Today found that 23% of long-term Elmiron users in Texas showed early macular changes, compared to 6% in the general population. This data is being used to establish causation in new filings.
“The latency period between Elmiron use and vision loss can exceed seven years. Many Texas patients only discovered they had pigmentary maculopathy during routine eye exams in 2023 or 2024. Our firm is actively reviewing cases where the statute of limitations may still apply under Texas’s discovery rule.” — Source: F1000Prime and archived reference
Key Diagnostic Markers Texas Attorneys Use in Pigmentary Maculopathy Claims
Proving pigmentary maculopathy in court requires objective evidence. Texas injury lawyers collaborate with retinal specialists to document these specific markers, which we’ve summarized below based on 2026 clinical guidelines:
| Diagnostic Marker | Description | Relevance to Elmiron Cases |
|---|---|---|
| Vitelliform lesions | Yellowish subretinal deposits | Present in 70% of Elmiron-related maculopathy cases |
| Optical coherence tomography (OCT) thinning | Reduced retinal pigment epithelium thickness | Correlates with cumulative drug exposure >500g |
| Fundus autofluorescence (FAF) patterns | Hyperautofluorescent spots in macula | Distinguishes Elmiron toxicity from age-related macular degeneration |
| Multifocal ERG abnormalities | Reduced electrical responses in central retina | Confirms functional vision loss even with normal visual acuity |
These markers are now standard in Texas expert witness testimony. A 2026 ruling in Harris County District Court allowed a retinal specialist’s OCT analysis as admissible evidence, setting a precedent for similar cases statewide.
Why the 2026 FDA Safety Communication Still Matters for Texas Claims
In June 2026, the FDA issued a new safety communication urging Elmiron prescribers to conduct annual retinal screenings for all current users. While this is a step forward, it does not address the thousands of Texas patients who took the drug before 2020. Many of these individuals were diagnosed with “idiopathic” maculopathy—a misdiagnosis that delayed their legal claims.
Texas injury lawyers are now leveraging the FDA’s updated label to argue that Janssen knew or should have known about the risk by 2018, based on a Kaiser Permanente study that first linked Elmiron to retinal toxicity. The statute of limitations in Texas is generally two years from discovery, but courts have allowed claims filed as late as 2025 when the patient’s vision loss was initially attributed to aging or genetics.
- Key deadline: Texas patients who stopped Elmiron in 2020 and were diagnosed in 2024 may still file claims through 2026 under the discovery rule.
- Compensation ranges: Settlements for Elmiron maculopathy cases in Texas have ranged from $150,000 to $2.5 million, depending on vision loss severity and duration of drug use.
- Attorney requirements: Texas law requires injury lawyers to prove both medical causation and failure to warn. Firms now routinely hire board-certified retinal specialists as consultants.
As we move through 2026, the Elmiron litigation remains a cautionary tale about the gap between drug approval and post-market surveillance. Texas patients who used Elmiron for IC should schedule a comprehensive eye exam immediately—even if they have no symptoms—and consult with an attorney experienced in pigmentary maculopathy cases. The window for filing claims is narrowing, but for those with documented retinal damage, justice is still within reach.